Related Experiment Video

Updated: Aug 22, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Successful targeting of ErbB2 receptors-is PTEN the key?

Robert J Crowder1, Donald P Lombardi, Matthew J Ellis

  • 1Department of Medicine, Division of Oncology, Washington University School of Medicine and Siteman Cancer Center, Campus Box 8056, 660 South Euclid Avenue, St. Louis, MO 63110, USA.

Cancer Cell
|August 25, 2004
PubMed

Insights

Trastuzumab, an ErbB2-targeted therapy, improves survival in breast cancer by activating PTEN, which downregulates the PI3K pathway. Loss of PTEN function leads to resistance, highlighting PTEN

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • ErbB2-positive breast cancer presents a poor prognosis with often ineffective chemotherapy.
  • Trastuzumab, an antibody targeting ErbB2, enhances survival in metastatic disease but is not curative and faces common primary resistance.

Purpose of the Study:

  • To investigate the mechanism of action for trastuzumab in ErbB2-positive breast cancer.
  • To elucidate the role of PTEN (Phosphatase and tensin homolog) in trastuzumab efficacy and resistance.

Main Methods:

  • The study investigated the molecular effects of trastuzumab treatment.
  • Analysis focused on the phosphatidylinositol 3'-kinase (PI3K) pathway and PTEN activity.

Main Results:

  • Trastuzumab rapidly activates the PTEN lipid phosphatase.
  • PTEN activation leads to the downregulation of the PI3K pathway.
  • Loss of PTEN function was identified as a mechanism of resistance to trastuzumab.

Conclusions:

  • PTEN activation is a critical component of trastuzumab's therapeutic effect in ErbB2-positive breast cancer.
  • Understanding the PTEN-PI3K axis is crucial for overcoming trastuzumab resistance.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: